Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153
Authors:
Hun Ju Lee
Michael Y. Choi
Tanya Siddiqi
Joanna Rhodes
William G. Wierda
Iris Isufi
Joseph M. Tuscano
Nicole Lamanna
Suki Subbiah
Jean L. Koff
Lori A. Leslie
Alec Goldenberg
Gina G. Chung
James B. Breitmeyer
Salim Yazji
Michael Wang
Catriona Jamieson
Thomas J. Kipps
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Epidemiology and Treatment of Childhood Leukemia (OpenAlex Topic)
Related Items:
Conference Proceeding
Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440
Publication Date
View
OpenAlex Record
PubMed Record
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2022-167153
DOI:
10.1182/blood-2022-167153
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: